694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

• Bart Neyns,
• Bart Ilsen,
• Jens Tijtgat,
• Frederik Vandenbroucke,
• Inès Dufait,
• Sandra Tuyaerts,
• Ivan Van Riet,
• Xenia Geeraerts,
• Latoya Stevens,
• Manon Vounckx,
• Iris Dirven,
• Steven Raemaeckers,
• Selma Ben Mustapha,
• Jens Van Loon,
• Lore Decoster,
• Mark De Ridder

Affiliations

Bart Neyns

Department of Medical Oncology, UZ Brussel, Brussels, Belgium

Bart Ilsen

4 Department of Radiology, University Hospital UZBrussel, Vrije Universiteit Brussel, Brussels, Belgium

Jens Tijtgat

2 Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Frederik Vandenbroucke

Radiology, UZ Brussel, Brussels, Belgium

Inès Dufait

Department of Radiotherapy, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Sandra Tuyaerts

Department of Medical Oncology/Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Ivan Van Riet

1UZ Brussel, Jette, Belgium

Xenia Geeraerts

2Vrije Universiteit Brussel, Jette, Belgium

Latoya Stevens

2Vrije Universiteit Brussel, Jette, Belgium

Manon Vounckx

1UZ Brussel, Brussels, Belgium

Iris Dirven

1UZ Brussel, Brussels, Belgium

Steven Raemaeckers

1UZ Brussel, Brussels, Belgium

Selma Ben Mustapha

1UZ Brussel, Brussels, Belgium

Jens Van Loon

1UZ Brussel, Brussels, Belgium

Lore Decoster

1UZ Brussel, Brussels, Belgium

Mark De Ridder

1UZ Brussel, Brussels, Belgium